Diabetes Mellitus Clinical Trial
Official title:
An Evaluation of a Coordinated Proactive Diabetes Eye Care Program
The study's primary objective is to determine whether the PRSS improves the optimal timing of photocoagulation in diabetic patients in VA. Secondary objectives include assessing if the program: (1) leads to improved compliance with retinopathy screening and surveillance visits; (2) improves patient and provider satisfaction with VA diabetic eye care; (3) reduces eye care visit rates among diabetics receiving eye care at VA; (4) decreases health care resource utilization; and (5) improves the cost-effectiveness of eye care for patients with diabetes
Diabetes is a common cause of blindness and much of this blindness is preventable by early
detection and treatment. Although VA and HEDIS quality criteria now allow some individuals
with diabetes to have biannual examinations, current diabetes eye care policies continue to
emphasize routine, annual eye exams for most diabetes patients. Strong evidence suggests
that the current �one-size fits all� method wastes resources while ignoring an opportunity
to substantially improve outcomes for high-risk patients.
Recent research shows that patients referred for screening examinations (i.e., those without
retinopathy) require different follow-up then those referred for surveillance examinations
(i.e., those with retinopathy). Using a more targeted, risk-based criteria for scheduling
eye examinations together with system level interventions designed to assure their
application may lead to improved healthcare outcomes. Although, the efficacy of such
approaches have been demonstrated in other systems and organizational research, it has not
yet been demonstrated for diabetes eye care.
Therefore, we propose to conduct and evaluate a prototype translational research project
examining the impact of the Proactive Diabetes Eye Care Program, a coordinated and targeted
system-level intervention, on: 1) the optimal timing of photocoagulation; 2) the optimal
timing of eye care visits; 3) patient and provider satisfaction; 4) health care resource
use; and 5) the overall cost-effectiveness of a targeted eye care program.
The primary intervention will involve the use of an innovative �Progressive Reminder and
Scheduling System� in which intensity of the reminders is based on the patient�s degree of
risk for developing proliferative diabetic retinopathy or macular edema. At the intervention
sites, there will be separate clinics for screening (those whose last examination was
normal) and surveillance (those with known retinopathy). This two-year prototype
translational project will have a quasi-experimental design. Six facilities will be
recruited: three will receive the intervention without the system design components. The
control and intervention sites will be matched for comparability to baseline screening rates
and similar patient populations. The intervention will be evaluated using historical
controls (pre-post analyses) and by comparison to control sites.
Data will be collected from three sources. We will use the VISTA database to determine
resource use, patients demographics, co-morbidities and medications. Trained medical
personnel will conduct chart reviews on a random sample of patients undergoing
photocoagulation to determine whether it was sub-optimally timed (i.e., the patient already
had a major retinal hemorrhage or advanced macular edema at the time of the procedure). A
random sample of patients will be surveyed, at baseline and after 12 months, about non-VA
eye care services they received and their attitudes and satisfaction toward eye care. We
will also survey health care providers regarding diabetic eye care services.
If successful, this program will serve as a model for disseminating diabetes eye care best
practices throughout the VA system and could provide further information about the best
approaches to managing other diseases in which patients may benefit from risk stratification
rather than being treated according to a single standard.
;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
| Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
| Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
| Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
| Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
| Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
| Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
| Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
| Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
| Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
| Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
| Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
| Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
| Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
| Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
| Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
| Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
| Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |